A Phase 1 Study of TPI 287 Concurrent With Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases From Advanced Breast and Non-Small Cell Lung (NSCL) Cancer.
Phase of Trial: Phase I
Latest Information Update: 02 May 2017
At a glance
- Drugs TPI 287 (Primary)
- Indications Brain metastases
- Focus Adverse reactions
- 20 Nov 2015 Results published in a Cortice Biosciences media release.
- 09 Nov 2015 Results from this trial will be presented at the 20th Annual Society for Neuro-Oncology Annual Scientific Meeting and Education Day according to a Cortice Biosciences media release.
- 29 May 2015 According to an abstract presented at 51st Annual Meeting of the American Society of Clinical Oncology 2 patients have been enrolled till date.